 TEL AVIV, Israel, April 14, 2021 GLOBE NEWSWIRE -- Vascular Biogenics Ltd. VBL Therapeutics or the Company NASDAQ: VBLT, today announced the closing of its underwritten public offering of 6,901,790 ordinary shares, and, to certain investors in lieu thereof, pre-funded warrants to purchase 8,050,000 ordinary shares in an underwritten public offering, at a price to the public of 1.90 per ordinary share and 1.89 per pre-funded warrant. The pre-funded warrants allow investors that have restrictions on their ability to own Company stock above a designated ownership threshold such as 4.99 or 19.99 to invest additional capital. In practice, the pre-funded warrants are the equivalent to ordinary shares without voting rights. All of the securities in the offering were sold by VBL Therapeutics. 